优化超声波辅助深层阳性溶剂的提取,表征和低血糖活性从阿布里草的多糖类的优化
Tao Yang1,2, Fengjuan Yang3, Danni Xu3
1School of Chemistry & Materials Science, Guangxi Minzu Normal University, Chongzuo, 532200, China. yangtao271218@outlook.com.
Applied biochemistry and biotechnology
|January 13, 2026
概括
超声波辅助的深溶剂有效地提取了阿布里赫巴多糖 (AHPs). 纯化的AHPs-1分量显示出显著的低血糖活性,表明功能性食品和药品的潜力.
科学领域:
- 自然产品化学 自然产品化学
- 生物化学 生物化学
- 食品科学 食品科学 食品科学
背景情况:
- 来自Abri Herba (AHPs) 的多糖具有潜在的生物活性.
- 有效和可持续的提取方法是需要AHPs.
研究的目的:
- 开发和优化超声波辅助的深度性溶剂 (DES) 方法用于AHP的提取.
- 描述提取的AHP并评估它们的低血糖潜力.
主要方法:
- 提取优化的Box-Behnken响应表面方法.
- 使用DES (胆化物:尿素) 的超声波辅助提取.
- 使用DEAE-52纤维素染色学进行净化.
- 通过HPSEC-MALLS-RID,FT-IR和SEM进行表征.
- 在体外低血糖活性测定 (α-葡萄糖酶和α-氨基酶抑制).
主要成果:
- 最佳的提取条件产生了8.49%的AHPs.
- 纯化的AHPs-1 (MW: 4.74 × 104 Da) 是同质的,具有粗的表面形态.
- FT-IR证实了多糖特征; 刚果红色试验排除了三重螺旋结构.
- AHPs-1对α-葡萄糖酶和α-氨基酶表现出显著的抑制作用.
结论:
- 建立了一种有效的基于DES的AHP提取方法.
- AHPs-1显示出有希望的低血糖特性.
- AHPs-1是功能性食品和制药应用的潜在候选者.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


